Wu Hao, Zhang Xian-Yu, Niu Ming, Li Fei-Feng, Gao Song, Wei Wei, Li Si-Wei, Zhang Xing-Da, Liu Shu-Lin, Pang Da
Genomics Research Center, College of Pharmacy, State-Province Laboratory of Biomedicine and Pharmaceutics of China, Harbin Medical University, Harbin, China.
Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital, Harbin, China.
Front Oncol. 2020 Oct 21;10:574552. doi: 10.3389/fonc.2020.574552. eCollection 2020.
Breast malignancy is a serious threat to women's health around the world. Following the rapid progress in the field of cancer diagnostics and identification of pathological markers, breast tumor treatment methods have been greatly improved. However, for invasive, ductal carcinomas and mammary fibroadenoma, there is an urgent demand for better breast tumor-linked biomarkers. The current study was designed to identify diagnostic and/or therapeutic protein biomarkers for breast tumors.
A total of 140 individuals were included, comprising 35 healthy women, 35 invasive breast cancers (IBC), 35 breast ductal carcinomas (DCIS), and 35 breast fibroadenoma patients. iTRAQ) proteomic analysis was employed to characterize differentially expressed proteins for potential biomarkers in IBC, DCIS, and fibroadenomas by comparisons with their matched adjacent tissues and/or normal breast tissues. The public databases Metascape and String were used for bioinformatic analyses.
Using the proteomics approach, we identified differentially expressed proteins in tissues of different breast tumors compared to normal/adjacent breast tissues, including 100 in IBC, 52 in DCIS, and 44 in fibroadenoma. Among the 100 IBC differentially expressed proteins, 37 were found to be specific to this type of cancer only. Additionally, four proteins were specifically expressed in DCIS and four in fibroadenoma. Compared to corresponding adjacent tissues and normal breast tissues, 18 step-changing proteins were differentially expressed in IBC, 14 in DCIS, and 13 in fibroadenoma, respectively. Compared to DCIS and normal breast tissues, 65 proteins were differentially expressed in IBC with growing levels of malignancy.
The identified potential protein biomarkers may be used as diagnostic and/or therapeutic targets in breast tumors.
乳腺恶性肿瘤对全球女性健康构成严重威胁。随着癌症诊断领域的快速发展以及病理标志物的识别，乳腺肿瘤治疗方法有了很大改进。然而，对于浸润性导管癌和乳腺纤维腺瘤，迫切需要更好的与乳腺肿瘤相关的生物标志物。本研究旨在鉴定乳腺肿瘤的诊断和/或治疗性蛋白质生物标志物。
共纳入140名个体，包括35名健康女性、35名浸润性乳腺癌（IBC）患者、35名乳腺导管原位癌（DCIS）患者和35名乳腺纤维腺瘤患者。采用iTRAQ蛋白质组学分析，通过与匹配的相邻组织和/或正常乳腺组织比较，鉴定IBC、DCIS和纤维腺瘤中差异表达的蛋白质作为潜在生物标志物。使用公共数据库Metascape和String进行生物信息学分析。
采用蛋白质组学方法，我们鉴定出与正常/相邻乳腺组织相比，不同乳腺肿瘤组织中差异表达的蛋白质，其中IBC中有100种，DCIS中有52种，纤维腺瘤中有44种。在IBC的100种差异表达蛋白质中，发现37种仅特异性表达于此类癌症。此外，有4种蛋白质在DCIS中特异性表达，4种在纤维腺瘤中特异性表达。与相应的相邻组织和正常乳腺组织相比，IBC中有18种阶梯变化蛋白差异表达，DCIS中有14种，纤维腺瘤中有13种。与DCIS和正常乳腺组织相比，随着恶性程度增加，IBC中有65种蛋白质差异表达。
鉴定出的潜在蛋白质生物标志物可作为乳腺肿瘤的诊断和/或治疗靶点。
